Objective: Anorexia nervosa is associated with social-emotional functioning deficits and low levels of the social neurohormone oxytocin, even after weight gain. The relationship between low oxytocin levels and social-emotional functioning impairment has not been studied. Results: Most measures of social-emotional functioning showed impairment in women with AN and AN-WR compared to H. Oxytocin levels were low in AN-WR compared to H. Across groups, low oxytocin levels were associated with difficulty identifying feelings (r 5 2.45, p 5 .008) and overall alexithymia (r 5 2.34, p 5 .0489).
| I N TR ODU C TI ON
Women with anorexia nervosa (AN) are at risk for premature mortality (Crow et al., 2009; Keshaviah et al., 2014) and demonstrate social functioning impairments, including social anxiety (Bulik, Beidel, Duchmann, Weltzin, & Kaye, 1991) , suspiciousness and insecure attachment (Holliday, Uher, Landau, Collier, & Treasure, 2006) , difficulty recognizing others' emotions (Jansch, Harmer, & Cooper, 2009; Russell, Schmidt, Doherty, Young, & Tchanturia, 2009) , and alexithymia (difficulty understanding one's own emotions; Bourke, Taylor, Parker, & Bagby, 1992; Lule et al., 2014) . Social-emotional functioning deficits predict poorer long-term outcomes in AN (Speranza, Loas, Wallier, & Corcos, 2007) and do not resolve with weight gain (Beadle, Paradiso, Salerno, & McCormick, 2013; Beales & Dolton, 2000; Coulon, Jeammet, & Godart, 2009; Holliday et al., 2006; Parling, Mortazavi, & Ghaderi, 2010; Speranza et al., 2007; Tchanturia et al., 2012) .
Oxytocin is an anorexigenic neurohormone that reduces food intake in animals and humans (Blevins & Baskin, 2015) and regulates social-emotional functioning. In animals, oxytocin has anxiolytic (Ring et al., 2006; Windle, Shanks, Lightman, & Ingram, 1997) and pro-social *Cindy Schmelkin and Franziska Plessow contributed equally to this work.
effects (Lukas et al., 2011; Pedersen & Prange, 1979) . When administered to humans, oxytocin increases gaze toward the eye region (Guastella, Mitchell, & Dadds, 2008) , trust (Kosfeld, Heinrichs, Zak, Fischbacher, & Fehr, 2005) , and, particularly in individuals with higher alexithymia scores, the ability to recognize emotional expressions (Aoki et al., 2014; Fischer-Shofty, Levkovitz, & Shamay-Tsoory, 2013; Guastella et al., 2010; Lischke et al., 2012; Luminet, Grynberg, Ruzette, & Mikolajczak, 2011; Marsh, Yu, Pine, & Blair, 2010) . Further, oxytocin administration increases the sharing of emotional experiences with others (Lane et al., 2013) . We have reported low basal serum oxytocin levels (compared to healthy women, H) in women with AN (Lawson et al., 2011) and those with a history of AN who are now weightrestored and in partial or full recovery (AN-WR; Afinogenova et al., 2016 [same study sample as described here]; Lawson et al., 2012) .
These data imply that basal oxytocin levels may be low in women with AN regardless of weight status and raise the question of whether low oxytocin levels may contribute to symptoms.
Whether low oxytocin levels in women with AN are related to difficulties in social-emotional functioning has not been studied. We therefore investigated the relationship between oxytocin levels and social-emotional functioning in women with AN, AN-WR, and H, hypothesizing that lower oxytocin levels would be associated with increased severity of social-emotional functioning impairment.
| M E TH OD

| Participants
We studied 79 ambulatory women (19 AN, 26 AN-WR, and 34 H), 18-45 years old. Clinical characteristics and oxytocin levels have been reported (Afinogenova et al., 2016) . Social-emotional functioning measures and their relationship to oxytocin levels have not been published. Kushner, Quilty, Tackett, & Bagby, 2011) , and the Toronto Alexithymia Scale (TAS-20; .
| Methods
Bionutritionists measured height, weight, and frame size (determined by comparing elbow breadth with race-specific norms derived from US National Health and Nutritional Examination Survey-I; Frisancho & Flegel, 1983) and calculated %IBW (using the Metropolitan height and weight tables, 1983) and body mass index (BMI). A fasting blood draw was performed.
| Psychological measures
On all of these well-validated self-report measures, higher scores indicate increased symptom severity. The EDE-Q, completed by all participants, measures eating disorder psychopathology (Fairburn & Beglin, 1994) . A global score plus subscales (dietary restraint, eating concern, shape concern, and weight concern) are calculated, ranging from 0 to 
| Biochemical analysis
Serum was stored at 2808C. Oxytocin was measured in unextracted serum by ELISA (Assay Designs, Inc., Ann Arbor, MI; Afinogenova et al., 2016) . We have demonstrated a robust correlation between extracted and unextracted serum oxytocin levels (Lawson et al., 2013) . The detection limit was 12.5 pg/mL. In-house QCs had a mean of 152 and 338 pg/mL and a between-assay CV of 15 and 18%, respectively.
| Data analysis
We used JMP 12 (SAS Institute, Inc., Cary, NC) for statistical analyses.
We compared clinical characteristics, psychiatric measures, and oxytocin levels using Fisher's Least Significant Difference test. We utilized Hedges' g to determine effect sizes for pairwise comparisons and Pearson's correlations to examine the relationship between oxytocin levels and psychological measures. To control for potential confounders (BMI SCHMELKIN ET AL.
| 1333
and amenorrhea), we used multivariate least square analyses. To analyze contributors to TAS-20 scores, we used hierarchical regression.
Data are reported as mean 6 standard error of measurement (SEM).
Statistical significance is defined as a two-tailed p value <.05. 
| R E SU LTS
| Clinical characteristics
| TAS-20
Difficulty describing feelings, difficulty identifying feelings, and total alexithymia scores were higher in participants with AN and AN-WR than H (p .002) and did not differ between participants with AN and 
| Relationship between oxytocin and socialemotional functioning
Across groups, oxytocin was negatively associated with difficulty identifying feelings (r 5 2.45, p 5 .008) and TAS-20 total score (r 5 2.34, p 5 .049; Figure 1 ). These relationships remained significant after controlling for BMI and estrogen status (presence or absence of amenorrhea; p 5 .005 and .02, respectively). There were no significant associations between oxytocin and other social-emotional measures (p .12).
In a hierarchical multiple regression model with oxytocin (step 1), BMI (step 2), and estrogen status (step 3), oxytocin and BMI accounted for 13.3% (p 5 .02) and 13.1% (p 5 .01) of variance in TAS-20 total score, respectively. Using the same model, oxytocin and BMI accounted for 20.3% (p 5 .005) and 11.3% (p 5 .07) of variance in difficulty identifying feelings, respectively.
| D I SCUSSION
To the best of our knowledge, our study is the first to show that low levels of the neurohormone oxytocin are associated with greater severity of alexithymia. This novel finding is important, because it raises the question of whether oxytocin might be a potential mediator of alexithymia, which predicts poorer outcomes in women with AN.
Oxytocin, a key hormone involved in social interaction, has been implicated in disorders involving social deficits, e.g., autism. we report significantly lower fasting serum oxytocin levels in women with AN-WR than healthy controls, while oxytocin levels in AN were numerically lower than those of healthy controls at the trend level.
Across all groups, we found that lower oxytocin levels were associated with increased alexithymia, in particular in identifying one's own feelings, independent of BMI and estrogen status. Whether oxytocin plays a role in the social-emotional functioning deficits observed in individuals with a life-time diagnosis of AN merits investigation.
Alexithymia is a well-described social-emotional functioning deficit in adult women and adolescents with AN (Corcos et al., 2000; Speranza et al., 2005; Speranza et al., 2007) and a poor prognostic factor. In a three-year prospective study of 63 women with AN and 39 with bulimia nervosa, the difficulty identifying feelings subscale of the TAS-20 was negatively associated with clinical improvement at follow-up (Speranza et al., 2007) . Furthermore, it has been hypothesized that deficits in emotional processing serve as a barrier to effective cognitive therapy (Jansch et al., 2009) . The recognition of oxytocin as a potential mediator of these processes is important, as identifying the underlying neurobiology is a critical step in developing targeted treatments and improving outcomes. A prior study showed an interaction between oxytocin receptor genotype and childhood attachment in predicting adult alexithymia as well as brain structure and functioning in regions involved in salience processing and mentalizing (Schneider-Hassloff et al., 2016) . Others have shown that administration of oxytocin improves key processes that are impaired in alexithymia: emotion recognition (Aoki et al., 2014; Fischer-Shofty et al., 2013; Guastella et al., 2010; Lischke et al., 2012; Luminet et al., 2011; Marsh et al., 2010) and emotion expression (Lane et al., 2013) , further emphasizing the link between oxytocin and social-emotional functioning. Based on this, oxytocin has recently been proposed as a potential novel therapy in patients with alexithymia. Our data linking low serum oxytocin levels to higher alexithymia scores in women with AN are consistent with these findings and support the hypothesis that low oxytocin might contribute to these symptoms. A study investigating the impact of single-dose intranasal oxytocin (40 IU) did not find evidence for an improvement of social-emotional functioning in AN (Leppanen, Cardi, et al., 2017) , and a recent meta-analysis showed improvements of social-emotional functioning following intranasal oxytocin administration in healthy individuals but not in clinical populations . However, it is important to note that these studies used supraphysiologic levels of oxytocin, while our study investigated the link between physiologic levels of oxytocin and socialemotional functioning. It is conceivable that the revealed link between oxytocin levels and total alexithymia and difficulty identifying feelings only exists within the physiologic range of oxytocin, which emphasizes the need for studies of endogenous oxytocin levels in this population.
Limitations of this study include its small sample size, which may have introduced bias and/or reduced our ability to detect associations between oxytocin levels and social-emotional functioning. Even so, we demonstrated correlations between oxytocin levels and measures of alexithymia. This is a cross-sectional study, and therefore causality cannot be determined. Longitudinal studies in larger sample sizes of women with AN will be important to investigate the role of oxytocin in impaired social-emotional functioning. In addition, future studies are required to identify factors explaining individual variance in oxytocin levels within individuals with current or past AN.
In summary, we demonstrate that low oxytocin levels are associated with increased alexithymia, independent of BMI and estrogen status. Further investigation is needed to determine whether low oxytocin levels contribute to symptoms of alexithymia in AN.
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